BerGenBio Cocktail Event at ASCO

Chicago, IL, June 2, 2018
BerGenBio is delighted to invite you to meet the company's management team & clinical investigators

for
COCKTAILS & CANAPES
and short presentations on 

selective AXL inhibitor bemcentinib (BGB324), 
in phase II clinical development as a potential cornerstone of cancer combination therapy.

- BerGenBio reception at ASCO -
The School of the Art Institute Ballroom
112 S Michigan Ave, Chicago, IL 60603

Saturday June 2nd 2018: 6-8 p.m. (Central)

General Agenda

The event will include an overview of BerGenBio's business and Phase II clinical trial updates for our lead product bemcentinib, a potent first-in-class, highly selective, and orally bioavailable small molecule AXL kinase inhibitor as potential cornerstone therapy for cancer. Trials include key combination therapies using immune checkpoint inhibitors (KEYTRUDA), targeted therapies and chemotherapy for NSCLC, AML,

Dr Jim Lorens
BerGenBio, CMO

image_7zfo53.png

Promising data highlighting bemcentinib´s potential to improve efficacy of checkpoint inhibitors
(Read here)

Dr Corey Hogaboam
Cedars-Sinai Medical

image_wk69fm.png

Promising preclinical data supporting AXL-ADC in cancer and bemcentinib in NASH and IPF
(Read here)

Dr David Gerber
UT Southwestern

image_qqgfkh.png

Highlights of bemcentinib in combo with erlotinib and combo with docetaxel in NSCLC
(Read here)

     

Dr Sonja Loges
Univ Medical Ctr Hamburg-Eppendorf

image_ujwdpx.png

Immune response in AML patients receiving bemcentinib monotherapy
(Read here)

Dr Oddbjørn Straume
University of Bergen

image_ch67gw.png

Strong recruitment and encouraging safety profile for bemcentinib in melanoma
(Read here)

Dr Matthew Krebs
The Christie

image_aadagt.png

Recruitment into first stage of Phase II NSCLC trial with bemcentinib and Keytruda complete
(Read here)

 

Register / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

BerGenBio [BGBIO:OS] NKr2,369 MM MCap
Ber­Gen­Bio ASA is a clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany fo­cused on de­vel­op­ing a pipe­line of first-in-class AXL ki­nase in­hibi­tors as a po­ten­tial corn­er­s­tone of com­bi­na­tion can­cer ther­a­py. The... [more in­for­ma­tion]

Event Contact

Thomas Hoffmann
The Trout Group, LLC

Location of the Event and Other Places